Charles River Laboratories Acquires Cognate BioServices

Charles River Laboratories Acquires Vigene Biosciences

May 17, 2021

Biotechnology

Charles River Laboratories agreed to acquire Vigene Biosciences, a Rockville, Maryland-based gene therapy CDMO, for $292.5 million in cash plus up to $57.5 million in contingent payments. The acquisition expands Charles River's cell and gene therapy contract development and manufacturing capabilities—adding CGMP viral vector and plasmid DNA production—and is expected to close in early Q3 2021.

Taconic Biosciences Acquires TransCure bioServices

January 20, 2026

Biotechnology

Taconic Biosciences has acquired TransCure bioServices SAS to create an integrated global translational research platform combining Taconic's genetically engineered and humanized mouse models with TransCure's preclinical in vivo services. The deal expands Taconic's capabilities across oncology, immunology, infectious disease, and advanced modalities while preserving TransCure's brand and operational structure to ensure continuity for employees and clients.

Solvias Acquires Cergentis

July 13, 2022

Biotechnology

Swiss analytical contract research and manufacturing company Solvias acquired Utrecht-based genomics services provider Cergentis on July 12, 2022. The deal adds Cergentis' proprietary Targeted Locus Amplification (TLA) genomic analysis capabilities to Solvias' biologics and cell & gene therapy testing platform to expand its advanced-therapy testing services globally.

BioAgilytix Acquires Cambridge Biomedical

November 4, 2019

Healthcare Services

BioAgilytix, a GHO Capital portfolio company, has acquired Cambridge Biomedical, a Cambridge, Massachusetts–based clinical research organisation specializing in large-molecule bioanalysis. The deal expands BioAgilytix's laboratory capacity and capabilities (including CLIA/CAP/GLP capabilities and PCR/molecular suites), broadens its geographic footprint into the Boston/Cambridge biotech cluster, and strengthens its cell- and gene-therapy bioanalytical offerings.

FairJourney Biologics Acquires Charles River Laboratories' South San Francisco Facility

March 3, 2025

Biotechnology

FairJourney Biologics S.A. has acquired Charles River Laboratories' South San Francisco site (formerly Distributed Bio), including facilities, staff, assets and proprietary antibody libraries and yeast display technology. The acquisition expands FairJourney's antibody discovery and engineering capabilities and establishes a strategic presence in a major U.S. biotech hub to better serve biopharma customers.

Agilent Technologies Acquires BIOVECTRA for $925M

July 22, 2024

Pharmaceuticals

Agilent Technologies has acquired BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO), for $925 million. The acquisition — a purchase from H.I.G. Capital — expands Agilent's CDMO capabilities across biologics, HPAPIs, pDNA/mRNA and LNP formulation, and integrates BIOVECTRA into Agilent's Diagnostics and Genomics Group.